CG
ALNY icon

Caprock Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Caprock Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$394K Buy
1,190
+198
+20% +$67.4K 0.01% 827
2025
Q4 		$394K Buy
992
+135
+16% +$59.7K 0.01% 898
2025
Q3 		$383K Buy
+857
New +$349K 0.01% 868

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caprock Group's ALNY Position: Q1 2026 in Review

Caprock Group increased its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q1 2026, buying an estimated $67.4K and bringing the position to 1,190 shares worth $394K. The position accounts for 0.01% of the portfolio, ranked #827.

Caprock Group first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $394K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Caprock Group held 1,190 shares of Alnylam Pharmaceuticals worth $394K as of Q1 2026.
  • Caprock Group bought 198 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $67.4K.
  • Alnylam Pharmaceuticals made up 0.01% of Caprock Group's portfolio in Q1 2026, its #827 holding.
  • Caprock Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Caprock Group's Alnylam Pharmaceuticals position peaked at $394K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.